RCS - Synairgen PLC - Board and Executive Leadership Changes

SynairgenAnnouncement

16/05/2025 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250516:nRSP9198Ia&default-theme=true

RNS Number : 9198I  Synairgen PLC  16 May 2025

 

Synairgen

('Synairgen' or the 'Company')

Board and Executive Leadership Changes

Southampton, UK - 16 May 2025: Synairgen, the respiratory company developing
SNG001, an investigational formulation for inhalation containing the
broad-spectrum antiviral protein interferon beta, today announces a number of
changes in the executive leadership of the company.

Mr Richard Marsden will step down from the role of Chief Executive Officer and
as Company Director and Board member with effect from 1 July 2025.  As part
of the transition of leadership of the Company, Mr Marsden will be retained as
a part-time Board Advisor to maintain continuity and to ensure his significant
expertise in the field is secured for the Company.

Mr Joseph Colliver, currently Chief Financial Officer, will step up to the
role of Chief Executive Officer.  Mr Colliver joined Synairgen in October
2023 and has a broad professional business background with a track record in
senior leadership roles, finance and fund raising, corporate transactions, and
commercial partnerships.

Dr Mark Parry-Billings who joined Synairgen as Non-Executive Chairman in
October 2024, will transition, also on 1 July 2025, to the role of Executive
Chairman maintaining his leadership of the Board whilst leveraging his pharma
and biotech R&D and business experience to further support the Company's
core program.

Dr Parry-Billings added: "I would like to sincerely acknowledge Richard's
very significant tenure leading Synairgen as CEO for twenty years and his
material contributions to advancing the business and our programs.  Joseph is
a highly talented executive with the right skills to lead and drive the
company to its next value-inflection.  I am very much looking forward to
continuing the productive working relationship with both Joseph and Richard in
their new roles as we advance in the very high unmet medical need population
of mechanically-ventilated patients with viral pneumonia."

 

For further enquiries, please contact:

 Synairgen plc                                     + 44 (0)23 8051 2800
 Media@synairgen.com (mailto:Media@synairgen.com)

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on the development of
SNG001 (inhaled interferon beta) as potentially the first broad-spectrum
antiviral treatment delivered directly into the lungs for severe viral lung
infections.

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

For more information about Synairgen, please see www.synairgen.com
(http://www.synairgen.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUVUWRVBUVAAR